Prognostic value of prelymphodepletion absolute lymphocyte counts in relapsed/refractory diffuse large B-cell lymphoma patients treated with chimeric antigen receptor T cells

Frontiers in Immunology

Immunology

Yanyan Lu¹  Yang Liu¹  Yinxiang Sun¹  Feng Zhu¹  Haiying Sun¹  Kailin Xu¹  Jiang Cao¹  Wei Sang¹  Ying Wang¹  Depeng Li¹  Zhenyu Li¹  Hong Zhu¹  Hai Cheng¹  Zhiling Yan¹  Junnian Zheng² 

[1] Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China;Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China;Key Laboratory of Bone Marrow Stem Cell, Xuzhou, Jiangsu, China;Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China;Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou, Medical University, Xuzhou, Jiangsu, China;Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China;

关键词: chimeric antigen receptor T cell;    diffuse large B-cell lymphoma;    prelymphodepletion absolute;    prognostic value;    survival time;   

DOI  :  10.3389/fimmu.2023.1155216

 received in 2023-01-31, accepted in 2023-04-17,  发布年份 2023

来源: Frontiers

【 摘 要 】

IntroductionChimeric antigen receptor (CAR) T cell therapy has achieved unprecedented efficacy recently. However, the factors related to responses and durable remission are elusive. This study was to investigate the impact of pre-lymphodepletion (pre-LD) absolute lymphocyte count (ALC) on CAR T cell therapy outcomes.MethodsWe conducted a retrospective study of 84 patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) who underwent CAR T cell treatment at the Affiliated Hospital of Xuzhou Medical University between March 1,2016 and December 31, 2021. The enrolled patients were divided into high group and low group according to the optimal cutoff value of pre-LD ALC. The Kaplan-Meier analyses was used to calculate survival curves. The Cox proportional hazards model was used for univariate and multivariate analysis to assess the prognostic factors.ResultsThe ROC showed that the optimal cutoff value of pre-LD ALC was 1.05 x 109/L. The overall response (defined as partial response or complete response) rate was significantly higher in patients with a high pre-LD ALC (75% versus 52.08%; P=0.032). Patients with a low pre-LD ALC had significantly inferior overall survival (OS) and progression-free survival (PFS) compared with those having a high pre-LD ALC (median OS, 9.6 months versus 45.17 months [P=0.008]; median PFS, 4.07 months versus 45.17 months [P= 0.030]). Meanwhile, low pre-LD ALC is an independent risk factor for PFS and OS.DiscussionThe data suggested that pre-LD ALC may serve as a helpful indicator to predict the outcomes of CAR T cell therapy in patients with R/R DLBCL.

【 授权许可】

Unknown   
Copyright © 2023 Lu, Zhu, Liu, Wang, Sun, Cheng, Yan, Cao, Sang, Zhu, Li, Sun, Zheng, Xu and Li